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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
itraconazole is effective in the treatment of patients diagnosed with tinea versicolor and if so, 
what is the optimal dosage. 
 
STUDY DESIGN: Review of three peer-reviewed, randomized control trials (RCTs), two of 
which were published in 2002 and one in 2010. 
 
DATA SOURCES: Studies were researched through PubMed and selected based on the type of 
study (RCT), their relevance to the clinical question, and if they were POEMS (patient oriented 
evidence that matters). 
 
OUTCOME(S) MEASURED: Patient’s subjective measurement of the severity of pruritis, 
erythema, scaling, and pigment changes after treatment. Outcomes were also measured by a 
Wood’s lamp examination and a KOH preparation. 
 
RESULTS: Itraconazole was shown to be effective in treating tinea versicolor both clinically and 
mycologically. Patients reported a decrease in scaling, pigment changes, and pruritis, and their 
Wood’s lamp examination and KOH preparation were also negative. Of the two studies that 
reported p-values, one showed that the results were statistically significant (p <0.001) and the 
other showed the opposite (p>0.05).  
 
CONCLUSIONS: All three studies showed that itraconazole produced favorable results in the 
treatment of tinea versicolor and a single dose was an effective alternative to a seven day 
regimen. A single dose is also more advantageous because of decreased cost and increased 
compliance. Itraconazole is also effective as prophylaxis for tinea versicolor when taken one day 
each month. 
 
KEY WORDS: itraconazole, tinea versicolor 
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INTRODUCTION 
 Tinea versicolor, also known as pityriasis versicolor, is a chronic superficial fungal 
infection of the skin, most commonly occurring on the upper trunk. It is caused by Malassezia 
which is a normal colonizer of human skin. When Malassezia grows in excess on the skin, it can 
lead to this infection.
1
 Risk factors for the overgrowth of Malassezia include warm, humid 
environments, immunosuppression, malnutrition, corticosteroid usage, and possibly a genetic 
predispostion.
2
 Although tinea versicolor is considered a chronic infection with high rates of 
reoccurrence, there are both topical and systemic treatments available to either eradicate the 
current infection or serve as prophylaxis.  This paper evaluates three randomized control trials 
(RCTs) comparing either two doses of itraconazole or itraconazole versus a placebo to determine 
which is more efficacious in the treatment of tinea versicolor.  
 Tinea versicolor affects people worldwide, and it is most common in the tropical 
climates, due to warm, humid environments being a risk factor for the overgrowth of Malassezi. 
In the US the prevalence of tinea versicolor is estimated to be 2-8%. The precise number is 
unknown because most people do not seek medical attention when this infection occurs.
2
 The 
annual health care cost of tinea versicolor is unavailable. Due to the broad spectrum of fungal 
infections that intraconazole is used to treat, there is no data regarding the annual cost of 
itraconazole in the treatment of tinea versicolor. The most recent data published regarding the 
amount of health care visits per year for tinea versicolor infections was in 2004, in which there 
were approximately 2.9 million visits in the US alone.
3 
 
 Tinea versicolor affects all races, although it is more apparent in darker skinned 
individuals and it is most common in the age range of 15-24 years old due to increased activity 
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of sebaceous glands.
2 
The infection may be asymptomatic but in some patients, the symptoms 
that capture their attention include tan, pink, or white colored macules that do not tan in the 
summertime and pruritis. The macules have scales and may be located anywhere on the body but 
they are most commonly seen on the trunk. Tinea versicolor is not contagious because it is a 
normal pathogen of human skin. This infection is considered benign; therefore there is no 
significant morbidity and mortality.
2 
Most patients will experience reoccurrences of this 
infection, with rates reaching as high as 60% within one year and 80% within two years.
4 
 There are many treatments available to treat tinea versicolor including both topical and 
systemic agents. Some of the topical agents include selenium sulfide shampoo, ketoconazole 
shampoo, zinc pyrithione shampoo, miconazole, clotrimazole, terbinafine, salicylic acid, and 
benzyl peroxide. Systemic agents include ketoconazole, fluconazole, and itraconazole.
1, 2, 5 
 Although itraconazole is already being used to treat tinea versicolor, the researchers 
wanted to compare the effectiveness of a single dose versus a seven day treatment because it 
would allow for a decreased cost and increased compliance. Also the researchers wanted to look 
at itraconazole as a prophylactic agent for tinea versicolor due to the high rates of reoccurrence.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not itraconazole is 
effective in the treatment of patients diagnosed with tinea versicolor and if so, what is the 
optimal dosage. 
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METHODS 
 Certain criteria were used to select appropriate studies on this topic. This criteria included 
a population of patients who were clinically diagnosed with tinea versicolor by a Wood’s lamp 
examination or by KOH preparation, and the majority of patients were over 18 years old, non-
pregnant, and had not been using an antifungal treatment. The interventions in these studies 
included the use of itraconazole 400mg for one day or itraconazole 200mg BID one day per 
month for six months. In two of the articles, comparisons were made between the treatment 
group which received itraconazole 400mg for one day versus the control group who received 
itraconazole 200mg for seven days. In the last article, itraconazole 200mg BID one day per 
month for six months was given to the treatment group and compared to the control group which 
received placebo pills BID one day per month for six months. Outcomes measured the efficacy 
of itraconazole in the curative treatment of tinea versicolor which was based off of decreased 
pruritis, scaling, and hypopigmentation.  
 All three of the studies were RCTs that were published in peer-reviewed journals and in 
the English language, with one of the studies being double blinded. Key words utilized to search 
for these RCTs included “itraconazole” and “tinea versicolor”. The articles were researched 
through PubMed and selected based on the type of study (RCT), their relevance to the clinical 
question, and if they were POEMS (patient oriented evidence that matters). The inclusion criteria 
included RCTs published after 1996 and patients who were clinically diagnosed with tinea 
versicolor by a Wood’s lamp examination or KOH preparation. Exclusion criteria varied among 
the studies but included criteria such as age <18 years old, pregnant women, and the use of 
antifungals prior to the study. The full exclusion criteria can be seen in Table 1. A summary of 
the statistics reported or used in the trials include RBI, ABI, NNT, and p-values.  
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Table 1: Demographics & characteristics of included studies 
Study Type # Pts Age (yrs) Inclusion 
criteria 
Exclusion criteria W/D Interventions 
Kose 
(2002)
4 
RCT 50 For 
experimental 
group: 20 + 
41 
For control 
group: 21 + 
38 
Diagnosis of 
tinea versicolor 
based off of a 
positive KOH 
solution and 
Wood’s lamp 
exam 
Age <18yrs; 
women of 
childbearing age; 
no systemic 
antifungal intake 
prior to the study 
0 Use of 
itraconazole 
400mg 
x1day 
compared to 
control 
group using 
itraconazole 
200mg x7d 
Wahab 
(2010)
5 
RCT 60 Group A: 32 
+ 9 
Group B: 33 + 
8 
Diagnosis of 
tinea versicolor 
based off of a 
Wood’s lamp 
exam and KOH 
solution 
Age <18 yrs; 
pregnancy and 
topical and 
systemic 
antifungal agents; 
localized lesions, 
serious systemic 
illness 
0 Use of 
itraconazole 
400mg 
x1day 
compared to 
control 
group using 
itraconazole 
200mg x7d 
Faerge
mann 
(2002)
6 
Double 
blind 
RCT 
209 Group A 
(itraconazole): 
12-62, avg 30 
Group B 
(placebo): 12-
65, avg 30  
12-70 yrs old 
with a diagnosis 
of tinea 
versicolor 
confirmed by 
mycological 
exam 
Pts with: known 
sensitivity to 
itraconazole, 
chronic 
mucocutaneous 
candidiasis or 
systemic fungal 
infection, 
immunosuppressio
n, any other 
disease in the 
investigators’ 
opinion should 
exclude the pt, 
participated in 
drug trial within 
30 days, pregnant 
or breastfeeding, 
women of 
childbearing 
potential without 
adequate 
contraception 
4 Prophylactic 
treatment: 
Itraconazole 
200mg OR 
Placebo BID 
1 day per 
month x6 
months  
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OUTCOMES 
 The outcomes measured in these studies were POEMS, which included the patient’s 
subjective measurement of the severity of pruritis, erythema, scaling, and pigment changes. They 
were also measured by the investigator which was based off of a negative Wood’s lamp 
examination and a negative KOH preparation. 
4, 5, 6 
RESULTS 
 Study 1. In the Kose study 50 patients with recurrent and/or extensive tinea versicolor 
were enrolled, and all 50 completed the treatment. They all had a positive KOH preparation and 
Wood’s lamp examination. They had not received any topical antifungal treatment for two weeks 
prior and no systemic antifungal treatment prior to this study. They were broken down randomly 
into two groups: the treatment group which received itraconazole 400mg one dose and the 
comparison group which received itraconazole 200mg/d for seven days. The patients were 
evaluated clinically and mycologically before treatment began, at three weeks, and at six weeks 
which was the end of the study. Clinically they received a grade based on the scaling, 
hyper/hypopigmentation, and pruritis. They were scored 0=absent, 1= mild, 2= moderate, 3= 
severe. The mycological evaluation included KOH preparation and Wood’s lamp examination, 
and these were performed at each visit as well. At the end of the six weeks it was found that 
there was no difference between the two regimens both clinically and mycologically in clearing 
the tinea versicolor. The group that received one day of itraconazole had an 82% clinical cure 
rate while the group receiving seven days of itraconazole had an 84% clinical cure rate.
6
 Table 2 
summarizes the results for the Kose study, including a p-value of >0.05 indicating that the study 
may not be statistically significant. NNT shows a value of -50 which can be interpreted as having 
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to treat 50 people in order for one less beneficial outcome to occur compared to the control 
group.
 
Table 2: Kose Study: Itraconazole 400mg x 1 dose vs. Itraconazole 200mg/d x 7 days 
CER (7 days) EER (1 day) RBI ABI NNT p-value 
0.84 0.82 -0.02 -0.02 -50 >0.05 
 
 Study 2. The Wahab study evaluated the same dosages of itraconazole as was done in the 
Kose study, and it was published eight years later. They had 60 patients who were all clinically 
diagnosed with tinea versicolor by KOH preparation and Wood’s lamp examination. They were 
broken down randomly into two groups: the treatment group which received itraconazole 400mg 
for one dose and the comparison group which received itraconazole 200mg/d for seven days. The 
patients were evaluated four weeks and eight weeks after the start of treatment. There were three 
levels of clinical response: a cure was defined as complete clearing of the lesions, with negative 
Wood’s lamp and KOH preparation, improvement was defined as maximum clearing of lesions 
with or without negative Wood’s lamp and KOH preparation, and failure was defined as slight 
improvement, unchanged or deteriorating without negative Wood’s lamp and KOH preparation. 
This study had similar results to the prior study performed by Kose. At the end of the treatment 
there was not a large difference between the two treatment groups in clearing the tinea 
versicolor. In the group that received one day of itraconazole, 73% were cured and 17% were 
improved. In the group that received seven days of itraconazole, 80% were cured and 13% were 
improved.
5
 Table 3 summarizes the results for the Wahab study. A value of -15 for NNT means 
that 15 people would need to be treated in order to achieve one less beneficial outcome.  
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Table 3: Wahab study: Itraconazole 400mg x 1 dose vs. Itraconazole 200mg/d x 7 days 
CER (7 days) EER (1 day) RBI ABI NNT p-value 
0.80 0.733 -0.084 -0.067 -15 Not reported 
 
 Study 3. The final study by Faergemann was a double blind RCT which included 238 
patients with tinea versicolor who received an open treatment of itraconazole 200mg/d for seven 
days. The following four weeks they did not receive any treatment. After the four weeks were 
over, they returned to move onto the prophylactic treatment. Twenty-nine patients did not return 
for the second phase. The remaining patients were tested with light microscopy to make sure 
they were mycologically negative for tinea versicolor before continuing on with treatment. The 
patients were randomly assigned to two groups for the double blind prophylactic treatment. 
Group 1 received itraconazole 200mg BID one day per month for six months, and group 2 
received placebo pills BID one day per month for six months. Findings were scored as either 
cured, marked improvement, moderate improvement, unchanged, or deteriorated. When patients 
subjectively scored the variables at the end of the treatment, including hypopigmentation, 
pruritis, and erythema, they were significantly higher in the itraconazole group compared to the 
placebo group. At the end of the prophylactic phase, 88% of patients in the itraconazole group 
were still mycologically negative and 57% of patients in the placebo group were still 
mycologically negative.
4 
Table 4 summarizes the results for the Faergemann study, including a 
p-value of <0.001 indicating that the study was statistically significant. NNT in this study is 4, 
meaning that 4 people need to be treated with the regimen in the study to have one more 
beneficial outcome.  
Pachutski, Itraconazole & Tinea Versicolor 8 
 
 
Table 4: Faergemann study: Itraconazole 200mg vs placebo BID 1d/month x 6 months 
CER 
(placebo) 
EER 
(itraconazole) 
RBI ABI NNT p-value 
0.566 0.88 0.555 0.314 4 <0.001 
 
Safety and adverse events. In the Kose and Wahab studies, a complete blood count, liver 
function tests, and renal function tests were checked for each patient before they started the 
treatment. At week three of treatment, the patients in the Kose study were retested and had no 
abnormalities in their blood work. All three studies reported adverse events in some of the 
patients. In the Kose study five patients had adverse effects including fatigue, nausea, and 
abdominal pain.
6
 In the Wahab study five patients complained of dyspepsia, nausea, and 
flatulence.
5
 In the Faergemann study 26 patients reported adverse effects during open treatment 
and 31 patients during the prophylactic phase. One patient experienced urticaria during the open 
phase and was withdrawn from the study. Other patients experienced mild adverse effects 
including gastrointestinal complaints in the open phase, while during the prophylactic phase 
some patients encountered upper respiratory tract infections and influenza like symptoms.
4 
DISCUSSION 
 The goal of this systematic review was to determine whether or not itraconazole was 
effective in treating tinea versicolor and if so, what the optimal dosage is. All three of the studies 
demonstrated the effectiveness of itraconazole in treating tinea versicolor both clinically and 
mycologically. There were some limitations of the studies due to the fact that only one of them 
was double blinded. Also the studies did not mention if the patients were required to report to the 
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hospital each time they received a dose of medication, therefore treatment adherence may have 
been a complication and skewed the results. Patients that were required to take the medication 
for seven days may have not been compliant with the regimen compared to the patients that only 
had to take a single dose of itraconazole.  
There were restrictions in these three studies due to the fact that the majority of patients 
were men. In the Kose study, 37 patients were male and 13 were female.
6 
In the Wahab study, 53 
patients were male and 7 were female.
5 
In the Faergemann study, 116 patients were male and 93 
were female.
4 
The studies excluded pregnant females and females of child bearing age who did 
not have access to contraception. This may be because itraconazole is a pregnancy category C 
drug meaning that animal studies have shown an adverse effect on the fetus but there are no 
adequate, well-controlled studies in humans.
7 
These three studies also were limited based on age 
because they did not include children less than 18 years old in two of the studies and less than 12 
years old in the third study, therefore the results may not be applicable to children. In the Kose 
and Wahab studies, the mean duration that the patients had the tinea versicolor infection was 
approximately 2-3 months, therefore the results may not be applicable to patients that have had a 
tinea versicolor infection for a longer period of time. Lastly, race was not mentioned in the Kose 
and Wahab studies, but in the Faergemann study it showed that the majority of patients were 
Caucasian, with Asians being the next predominant race. Thus, the results may not be relevant 
for patients of other races.    
 Itraconazole is similar in price as other antifungals and is available as a generic 
prescription, so price should not be a concern for patients. It is also used to treat various fungal 
infections such as aspergillosis, histoplasmosis, candidiasis, onychomycosis in both HIV infected 
and non-HIV infected patients. The most common adverse effect of itraconazole is nausea. 
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Patients may also experience diarrhea, vomiting, headache, rash, elevated liver function tests, 
pruritis, dizziness, fatigue, hypertension, hypokalemia, etc. There is also a black box warning for 
the use of itraconazole in a patient with congestive heart failure or any ventricular dysfunction.
7 
CONCLUSION 
 In conclusion, all of the studies showed that itraconazole is effective in treating tinea 
versicolor. In the Kose and Wahab studies, it was demonstrated that a single dose of itraconazole 
400mg is an effective alternative therapy to itraconazole 200mg for seven days. Using a single 
dose treatment would be more advantageous because it would be less expensive and there would 
not be problems with compliance as there may be with a seven day regimen. In the Faergemann 
study it was shown that itraconazole is also effective as prophylaxis for tinea versicolor. Further 
studies are warranted to prove the effectiveness of itraconazole as prophylaxis for a time period 
longer than six months, as was done in the Faergemann study. Also further studies should 
include double blinding, larger research groups, more female patients, various races, and a wider 
age distribution to include children and geriatric patients. Based on the information obtained 
from these three studies and the potential for future explorations, itraconazole has the potential to 
become a first line medication for both the treatment of and prophylaxis for tinea versicolor.  
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